PML risk with Gilenya prompts update to US prescribing information

The FDA has announced that it will update the information for Gilenya (fingolimod) after two possible cases of PML in people with MS taking this disease modifying drug in the USA.
Source: Multiple Sclerosis Trust - Category: Neurology Source Type: news